632.20 +7.68 (1.23%)
After hours: 7:54PM EDT
|Bid||628.00 x 800|
|Ask||630.00 x 3100|
|Day's range||624.00 - 660.00|
|52-week range||271.37 - 664.64|
|Beta (5Y monthly)||0.57|
|PE ratio (TTM)||31.37|
|Earnings date||03 Nov 2020 - 09 Nov 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||643.83|
Regeneron (REGN) beats on Q2 earnings and sales on solid performance of Dupixent and oncology drug, Libtayo.
Regeneron is among several drugmakers racing to develop a treatment for the novel coronavirus and earlier this week said its experimental COVID-19 antibody drug combination, REGN-COV2, prevented and treated the disease in rhesus macaques and hamsters. Continued lockdowns to curb the spread of the coronavirus have prompted patients to reschedule their hospital visits, weighing on sales of physician-administered drugs such as Regeneron's blockbuster drug Eylea. U.S. sales of Eylea, approved for treating wet age-related macular degeneration, fell to $1.11 billion from $1.16 billion, but came in above Wall Street estimates of $1.06 billion, according to brokerage Piper Sandler.
Regeneron (REGN) delivered earnings and revenue surprises of 14.93% and 9.05%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?